A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases | Zendy

Idit Melnik | Zendy; Michal Lotem | Zendy; Boris Yoffe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases

Author(s) -

Idit Melnik,

Michal Lotem,

Boris Yoffe

Publication year - 2013

Publication title -

case reports in oncological medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.173

H-Index - 7

eISSN - 2090-6714

pISSN - 2090-6706

DOI - 10.1155/2013/794239

Subject(s) - vemurafenib , medicine , melanoma , metastatic melanoma , lymph node , neoadjuvant therapy , oncology , surgery , cancer research , cancer , breast cancer

Vemurafenib is approved by the FDA for the management of unresectable or metastatic melanoma. However, its role as a neoadjuvant therapy has not been determined. We present the first documented case in which vemurafenib induced complete tumor necrosis of both lymph node and brain metastases within one month or less, an outcome that indicated that the patient was a good candidate for excisional surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research